Results 181 to 190 of about 2,120,441 (365)
When culture-based whole-genome sequencing can change management in severe ocular bacterial infections. [PDF]
Fenniri I, André C.
europepmc +1 more source
Using Kotter's Change Management Framework to Redesign Departmental GME Recruitment. [PDF]
Miles MC +8 more
europepmc +1 more source
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
Staging CT chest for cT1a renal masses: Does it change management? [PDF]
Ilangovan S +9 more
europepmc +1 more source
ABSTRACT Objective This analysis evaluates the effect of successful reperfusion on functional outcomes after MT, stratified by admission National Institutes of Health Stroke Scale (NIHSS) and Alberta Stroke Program Early CT Score (ASPECTS) as surrogates for clinical‐core mismatch, using multicenter registry data.
Felix Schlicht +53 more
wiley +1 more source
Legislation against girl circumcision: a cultural psychological understanding of prohibition
Ernst Patrick Graamans +2 more
doaj +1 more source
'Everybody's voice is important': using translational simulation as a component of change management. [PDF]
Oliver N, Twentyman K, Howie K.
europepmc +1 more source
Clinical Validation of Plasma p‐217tau in Neurological Diseases
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi +13 more
wiley +1 more source

